Molecular Dynamics Simulations Suggest Ligand’s Binding to Nicotinamidase/Pyrazinamidase

The research on the binding process of ligand to pyrazinamidase (PncA) is crucial for elucidating the inherent relationship between resistance of Mycobacterium tuberculosis and PncA’s activity. In the present study, molecular dynamics (MD) simulation methods were performed to investigate the unbinding process of nicotinamide (NAM) from two PncA enzymes, which is the reverse of the corresponding binding process. The calculated potential of mean force (PMF) based on the steered molecular dynamics (SMD) simulations sheds light on an optimal binding/unbinding pathway of the ligand. The comparative analyses between two PncAs clearly exhibit the consistency of the binding/unbinding pathway in the two enzymes, implying the universality of the pathway in all kinds of PncAs. Several important residues dominating the pathway were also determined by the calculation of interaction energies. The structural change of the proteins induced by NAM’s unbinding or binding shows the great extent interior motion in some homologous region adjacent to the active sites of the two PncAs. The structure comparison substantiates that this region should be very important for the ligand’s binding in all PncAs. Additionally, MD simulations also show that the coordination position of the ligand is displaced by one water molecule in the unliganded enzymes. These results could provide the more penetrating understanding of drug resistance of M. tuberculosis and be helpful for the development of new antituberculosis drugs.

[1]  G. Magni,et al.  Enzymology of NAD+ synthesis. , 1999, Advances in enzymology and related areas of molecular biology.

[2]  D. Mitchison,et al.  The curious characteristics of pyrazinamide: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[4]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[5]  C. Chipot,et al.  Overcoming free energy barriers using unconstrained molecular dynamics simulations. , 2004, The Journal of chemical physics.

[6]  A. Sauve,et al.  Characterization of nicotinamidases: steady state kinetic parameters, classwide inhibition by nicotinaldehydes, and catalytic mechanism. , 2010, Biochemistry.

[7]  Ying Zhang,et al.  Pyrazinamide Inhibits Trans-Translation in Mycobacterium tuberculosis , 2011, Science.

[8]  M. Hirata,et al.  pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil. , 2006, The Journal of antimicrobial chemotherapy.

[9]  M. A. Steele,et al.  The role of pyrazinamide in tuberculosis chemotherapy. , 1988, Chest.

[10]  I. Sugawara,et al.  Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. , 2007, Mini reviews in medicinal chemistry.

[11]  S. Cameron,et al.  Specificity and mechanism of Acinetobacter baumanii nicotinamidase: implications for activation of the front-line tuberculosis drug pyrazinamide. , 2009, Angewandte Chemie.

[12]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[13]  C. Brenner,et al.  NAD+ metabolism in health and disease. , 2007, Trends in biochemical sciences.

[14]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[15]  D. Gigot,et al.  Pre‐B‐cell colony‐enhancing factor, whose expression is up‐regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis , 2002, European journal of immunology.

[16]  K. Schulten,et al.  Free energy calculation from steered molecular dynamics simulations using Jarzynski's equality , 2003 .

[17]  Li-Jun Bi,et al.  Characterization of Mycobacterium tuberculosis nicotinamidase/pyrazinamidase , 2008, The FEBS journal.

[18]  A. Zaha,et al.  Characterization of pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis in Brazil , 2005, Antimicrobial Agents and Chemotherapy.

[19]  J. Moniz-Pereira,et al.  pncA Mutations in Pyrazinamide-Resistant Mycobacterium tuberculosis Isolates in Portugal , 2004, Antimicrobial Agents and Chemotherapy.

[20]  R. Gilman,et al.  Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis. , 2009, Tuberculosis.

[21]  J. Board,et al.  Ewald summation techniques in perspective: a survey , 1996 .

[22]  Qing-Chuan Zheng,et al.  Unbinding of glucose from human pulmonary surfactant protein D studied by steered molecular dynamics simulations , 2010 .

[23]  Mark D'Souza,et al.  From Genetic Footprinting to Antimicrobial Drug Targets: Examples in Cofactor Biosynthetic Pathways , 2002, Journal of bacteriology.

[24]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[25]  C. Jarzynski Equilibrium free-energy differences from nonequilibrium measurements: A master-equation approach , 1997, cond-mat/9707325.

[26]  K. Schulten,et al.  Calculating potentials of mean force from steered molecular dynamics simulations. , 2004, The Journal of chemical physics.

[27]  D. Osei-Hyiaman,et al.  Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China , 2000, Epidemiology and Infection.

[28]  Thomas Speck,et al.  Distribution of work in isothermal nonequilibrium processes. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[29]  D. Schnappinger,et al.  Biosynthesis and Recycling of Nicotinamide Cofactors in Mycobacterium tuberculosis , 2008, Journal of Biological Chemistry.

[30]  S. Norris,et al.  A plasmid‐encoded nicotinamidase (PncA) is essential for infectivity of Borrelia burgdorferi in a mammalian host , 2003, Molecular microbiology.

[31]  W. Sougakoff,et al.  Crystal Structure of the Pyrazinamidase of Mycobacterium tuberculosis: Insights into Natural and Acquired Resistance to Pyrazinamide , 2011, PloS one.

[32]  Hoover,et al.  Canonical dynamics: Equilibrium phase-space distributions. , 1985, Physical review. A, General physics.

[33]  A. Sauve NAD+ and Vitamin B3: From Metabolism to Therapies , 2008, Journal of Pharmacology and Experimental Therapeutics.

[34]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[35]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[36]  F. Portaels,et al.  Relationship between Pyrazinamide Resistance, Loss of Pyrazinamidase Activity, and Mutations in the pncA Locus in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[37]  W. Mcdermott,et al.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli. , 1967, The American review of respiratory disease.

[38]  C. Jarzynski Nonequilibrium Equality for Free Energy Differences , 1996, cond-mat/9610209.

[39]  S H Kim,et al.  Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. , 2001, Biochemistry.

[40]  D. Zuckerman,et al.  Efficient use of nonequilibrium measurement to estimate free energy differences for molecular systems , 2004, Journal of computational chemistry.

[41]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[42]  Ji-Long Zhang,et al.  Theoretical improvement of the specific inhibitor of human carbonic anhydrase VII , 2011, Comput. Biol. Chem..

[43]  M. Watarai,et al.  Brucella abortus nicotinamidase (PncA) contributes to its intracellular replication and infectivity in mice. , 2004, FEMS microbiology letters.

[44]  D S Chauhan,et al.  The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria. , 2006, The Journal of communicable diseases.